Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
FAK Inhibitor 14: Reading FAK-Driven Cancer Biology
2026-10-06
FAK Inhibitor 14 offers a focused chemical lens for studying how focal adhesion kinase signaling connects cell adhesion, migration, and tumor progression. This article interprets its research value through the PARP1/FAK/COL5A1 findings in cholesterol-adapted ovarian cancer while separating reported evidence from testable hypotheses.
-
JHU-083 and the Next Phase of Glutaminase Research
2026-10-06
JHU-083 offers a research lens on glutaminase-dependent glutamate biology in cerebral immune-cell models. This thought-leadership perspective connects experimental cerebral malaria research with emerging redox biology while distinguishing mechanistic hypotheses from evidence established in hepatic α-amanitin toxicity.
-
WDR36, Glycolysis, and Human Blastoid Formation
2026-10-05
A 2025 Advanced Science study links WDR36 to trophectoderm differentiation in human stem-cell-derived blastoids through glucose metabolism and an interaction with LDHA. The findings provide a mechanistic framework for studying early developmental arrest, while remaining preclinical because blastoids are models rather than implanted human embryos.
-
D-Lin-MC3-DMA Product Overview
2026-10-05
D-Lin-MC3-DMA, also written Dlin-MC3-DMA, is listed by APExBIO as an ionizable cationic liposome lipid for conceptual use in nucleic-acid delivery research. No matched paper evidence was provided, so performance, safety, and application claims remain unverified here.
-
miR-424/503 Links TGF-β to CDC25A Arrest
2026-10-04
The reference study identifies the miR-424/503 cluster as a post-transcriptional component of TGF-β-induced cell-cycle arrest in mammary epithelial cells. Its findings show that microRNA-mediated CDC25A suppression works alongside transcriptional repression and proteasomal degradation, refining the mechanistic model of TGF-β cytostasis.
-
Annexin V-HF647/PI Apoptosis Kit in ESCC
2026-10-03
Explore how the Annexin V-HF647/PI Apoptosis Kit can support careful interpretation of apoptosis-associated phenotypes in esophageal squamous cell carcinoma. This article connects dual-parameter cell-death readouts with the HOXC9–AKT/mTOR findings while clarifying what the assay can—and cannot—prove.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-10-02
This guide explains how to prepare and control 4-Hydroxytamoxifen (SKU B6167) for DMSO-based estrogen receptor modulation, cancer, apoptosis, and cardiac myocyte workflows. It is not appropriate for protocols requiring water or ethanol solubility, and the supplied dossier does not establish a universal concentration, exposure time, or endpoint.
-
Angiotensin 1/2 (5-7): Assay Design Guide
2026-10-01
Explore Angiotensin 1/2 (5-7), the H2N-Ile-His-Pro-OH peptide, through a practical framework for RAS, cardiovascular, and spike–receptor binding assays. This guide emphasizes fragment-aware controls, product handling, and the limitations of translating binding data into disease mechanisms.
-
BRD4770 and the Translational Logic of G9a Inhibition
2026-10-01
BRD4770 offers a mechanism-first way to interrogate G9a/EHMT2, H3K9 methylation, senescence, and cancer-cell proliferation. This article connects evidence from breast cancer pathway studies with PANC-1 research, while defining practical validation steps, translational boundaries, and opportunities for more rigorous epigenetic model selection.
-
GSTA1, Glutathione Loss, and α-Amanitin Toxicity
2026-09-30
A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective antioxidant enzyme. Through integrated omics, interaction studies, and genetic silencing, the work links NRF2-associated GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.
-
SUMO Protease (Ulp): Practical Cleavage Workflow
2026-09-30
SUMO Protease (Ulp) is a recombinant Ulp1 protease for removing SUMO fusion tags after affinity purification, enabling downstream protein structural and functional analysis. It is intended for SUMO-tagged constructs with the appropriate C-terminal Gly-Gly junction, not for unrelated affinity tags or nonspecific protein degradation.
-
Z-LEHD-FMK: Precision Caspase-9 Inhibition
2026-09-29
Z-LEHD-FMK helps separate caspase-9-dependent mitochondrial apoptosis from downstream executioner activity in cell, ischemia/reperfusion, cancer, and neuroprotection workflows. This guide combines time-resolved assay design, formulation guidance, orthogonal readouts, and troubleshooting for more interpretable apoptosis experiments.
-
When HRP Proximity Labeling Meets Serotonin
2026-09-29
Biotin-XX Tyramide Reagent enables membrane-impermeant HRP-mediated labeling of extracellular targets, but serotonin can suppress this chemistry in neuronal proximity-labeling workflows. This thought-leadership article connects the mechanistic finding to assay design, tyramide signal amplification, tissue imaging, and translational research strategy.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-28
Build a reproducible fluorescence workflow around the Cy3 Goat Anti-Mouse IgG (H+L) Antibody for mapping RNLS–PMCA4b signaling in NCI-H295R cells. The guide connects receptor-localization imaging with flow cytometry, western blotting, and controls that distinguish fluorescence from true pathway effects.
-
SpCas9 mRNA: A Translation-Aware Editing Strategy
2026-09-28
SpCas9 mRNA enables guide-directed editing while separating Cas9 delivery from DNA-vector expression. This article explains how its RNA design shapes experimental interpretation—and why cap-independent translation research should not be confused with performance evidence for capped Cas9 mRNA.